Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072150 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
A Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00072150: Completed Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
NCT00072150 is a Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 99-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072150, a Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of the urothelium.
Primary Outcome
95% confidence intervals will be computed using the binomial distribution.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (1)
California
- UCSF-Mount Zion - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-10 |
| Phase | Phase 2 |
What the finished NCT00072150 record still lists
NCT00072150 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 99-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (60% lower).
The record links to 10 conditions, with Recurrent Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00072150 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00072150 about?
NCT00072150 is a clinical study titled "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma". Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of the urothelium.
What is the current status of trial NCT00072150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2003-10.
What conditions does trial NCT00072150 study?
This clinical trial studies the following conditions: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Ureter Cancer, Stage III Bladder Cancer.
What interventions are being tested in trial NCT00072150?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00072150?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072150 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
COMPLETED · Phase 2
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
RECRUITING
-
Gene Therapy in Treating Patients With Advanced Bladder Cancer
COMPLETED · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia